Nitin Jain, MD

Articles

Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL

November 5th 2024

Panelists discuss how they evaluate patients for tumor lysis syndrome (TLS) risk, considering factors such as tumor burden, renal function, and prior therapies, and how this assessment influences their decision between prescribing a non-covalent BTK inhibitor or a venetoclax-based regimen for chronic lymphocytic leukemia treatment.

Application of Pirtobrutinib in R/R CLL: Expert Perspectives

November 5th 2024

Panelists discuss how utilizing pirtobrutinib in clinical practice, focusing on its application in patients who have developed resistance or intolerance to prior BTK inhibitors, as well as in those who have shown resistance to both BTK and BCL-2 inhibitors in chronic lymphocytic leukemia treatment.

Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial

October 29th 2024

Panelists discuss how the non-covalent BTK inhibitor pirtobrutinib has shown promising results in the BRUIN clinical trials for both BTK inhibitor-naive and previously treated chronic lymphocytic leukemia patients, reviewing key efficacy and safety data presented at recent hematology conferences.

Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL

October 29th 2024

Panelists discuss how they assess patients for resistance to first-line BTK inhibitor therapy in chronic lymphocytic leukemia, emphasizing the importance of clinical evaluation, laboratory testing, and genetic analysis in determining the presence and mechanisms of resistance to guide subsequent treatment decisions.

Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL

October 22nd 2024

Panelists discuss how treatment approaches are tailored differently for patients with rapid, aggressive chronic lymphocytic leukemia progression versus those with slower, less aggressive disease, considering factors such as urgency of intervention, choice of therapy intensity, and long-term management strategies.

Key Patient-Specific Factors Guiding Treatment Selection in CLL

October 22nd 2024

Panelists discuss how various patient-specific factors, including age, comorbidities, performance status, disease aggressiveness, symptoms, and biomarkers, are carefully considered to guide the selection of optimal treatment strategies for individuals with chronic lymphocytic leukemia (CLL).

Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL

October 15th 2024

Panelists discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in chronic lymphocytic leukemia (CLL), considering factors such as resistance mechanisms, toxicity profiles, and patient-specific characteristics.

The Current Treatment Landscape for R/R CLL

October 15th 2024

Panelists discuss the current standard of care and treatment landscape for patients with chronic lymphocytic leukemia.

Dr Jain on Treatment Considerations in the Frontline Management of CLL

October 9th 2024

Nitin Jain, MD, discusses current treatment options and considerations for the frontline management of CLL.

Dr. Jain on the Utility of UCART22 in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

January 7th 2022

Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Q&A: Early Treatment of CLL

January 5th 2022

Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.

Q&A: Modifying and Switching Therapies in CLL

January 5th 2022

Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.

Novel Treatments for the Management of CLL

January 5th 2022

Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.

Choosing the Appropriate Treatment Strategy in CLL

December 22nd 2021

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Using Noncovalent BTK Inhibitors for the Management of CLL

December 22nd 2021

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Resistance Mechanisms to BTKi in CLL

December 15th 2021

Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.

Role of Fixed-Dose Regimens in CLL

December 15th 2021

Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.

ELEVATE-RR and ALPINE Trials in Relapsed CLL

December 8th 2021

Richard R. Furman, MD, leads the discussion on clinical implications from head-to-head trials of BTK inhibitors in the relapsed setting for patients with CLL.

BTK Inhibitors in the Management of CLL

December 8th 2021

Nitin Jain, MD, and Richard R. Furman, MD, review available treatment options for the treatment of CLL and discuss the safety and tolerability of these therapies.

Dr. Jain on the Combination of Venetoclax and Ibrutinib in CLL

January 12th 2018

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).